PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+20.42%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$100M
AUM Growth
+$12.8M
(+15%)
Cap. Flow
+$4.19M
Cap. Flow
% of AUM
4.19%
Top 10 Holdings %
Top 10 Hldgs %
33.7%
Holding
128
New
12
Increased
26
Reduced
31
Closed
16
Avg Time Held
1.9
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tactile Systems Technology
TCMD
|
+$1.49M |
| 2 |
Surmodics
SRDX
|
+$1.2M |
| 3 |
AVP
Avon Products, Inc.
AVP
|
+$1.12M |
| 4 |
Assertio
ASRT
|
+$964K |
| 5 |
Apyx Medical
APYX
|
+$945K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioTelemetry, Inc.
BEAT
|
+$1.98M |
| 2 |
ePlus
PLUS
|
+$1.49M |
| 3 |
Boston Scientific
BSX
|
+$1.18M |
| 4 |
OUTR
OUTERWALL INC
OUTR
|
+$853K |
| 5 |
LeMaitre Vascular
LMAT
|
+$480K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.72% |
| 2 | Technology | 12.42% |
| 3 | Industrials | 8.59% |
| 4 | Consumer Staples | 7.17% |
| 5 | Communication Services | 2.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Axogen
AXGN
$2.06B
| $5.61M | 5.61% |
620,908
-11,000
| -2% | -$89.4K |
2013 Q3
12 quarters
|
|
2
NeoGenomics
NEO
$2.17B
| $5.39M | 5.39% |
655,800
-17,232
| -3% | -$145K |
2013 Q2
13 quarters
|
|
|
STJ
3
DELISTED
St Jude Medical
STJ
| $5.32M | 5.32% |
66,673
| – | – |
2013 Q2
13 quarters
|
|
|
4
Apyx Medical
APYX
$108M
| $3.37M | 3.37% |
647,035
+291,295
| +82% | +$945K |
2015 Q1
6 quarters
|
|
5
Rockwell Medical
RMTI
$30.9M
| $2.97M | 2.97% |
4,030
-321
| -7% | -$260K |
2013 Q2
13 quarters
|
|
|
CSII
6
DELISTED
Cardiovascular Systems, Inc.
CSII
| $2.65M | 2.65% |
111,600
| – | – |
2013 Q2
13 quarters
|
|
7
Altimmune
ALT
$449M
| $2.38M | 2.38% |
2,733
-147
| -5% | -$115K |
2013 Q2
13 quarters
|
|
|
8
LeMaitre Vascular
LMAT
$1.89B
| $2.2M | 2.2% |
110,883
-27,475
| -20% | -$480K |
2013 Q2
13 quarters
|
|
9
AtriCure
ATRC
$2.91B
| $1.93M | 1.92% |
121,700
+36,600
| +43% | +$563K |
2013 Q2
13 quarters
|
|
|
10
DELISTED
Assertio
ASRT
| $1.9M | 1.9% |
1,268
+768
| +154% | +$964K |
2013 Q3
12 quarters
|
|
|
SNAK
11
DELISTED
Inventure Foods, Inc.
SNAK
| $1.87M | 1.87% |
198,750
-1,000
| -0.5% | -$9.02K |
2013 Q2
13 quarters
|
|
12
Pfizer
PFE
$166B
| $1.85M | 1.85% |
57,579
-1,054
| -2% | -$35.2K |
2013 Q2
13 quarters
|
|
|
13
Tactile Systems Technology
TCMD
$508M
| $1.81M | 1.81% |
+96,961
| New | +$1.49M |
2016 Q3
0 quarters
|
|
14
DELISTED
Cogentix Medical, Inc.
CGNT
| $1.78M | 1.78% |
979,610
-36,461
| -4% | -$47.2K |
2015 Q2
5 quarters
|
|
15
Eli Lilly
LLY
$1.08T
| $1.58M | 1.58% |
19,700
| – | – |
2013 Q2
13 quarters
|
|
16
Idexx Laboratories
IDXX
$41.7B
| $1.58M | 1.58% |
14,000
| – | – |
2013 Q3
12 quarters
|
|
|
VYNT
17
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
| $1.51M | 1.51% |
5,764
+1,889
| +49% | +$579K |
2015 Q4
3 quarters
|
|
18
DELISTED
Cantaloupe
CTLP
| $1.35M | 1.35% |
240,400
+2,000
| +0.8% | +$9.86K |
2014 Q1
10 quarters
|
|
|
19
DELISTED
Surmodics
SRDX
| $1.32M | 1.32% |
+43,750
| New | +$1.2M |
2016 Q3
0 quarters
|
|
20
Microsoft
MSFT
$3.96T
| $1.29M | 1.29% |
22,460
+3,725
| +20% | +$210K |
2014 Q1
10 quarters
|
|
|
SVU
21
DELISTED
SUPERVALU Inc.
SVU
| $1.29M | 1.29% |
36,879
-285
| -0.8% | -$10.1K |
2013 Q2
13 quarters
|
|
|
AVP
22
DELISTED
Avon Products, Inc.
AVP
| $1.27M | 1.27% |
+224,500
| New | +$1.12M |
2016 Q3
0 quarters
|
|
|
ZIXI
23
DELISTED
Zix Corporation
ZIXI
| $1.24M | 1.24% |
301,549
-1,990
| -0.7% | -$7.86K |
2013 Q2
13 quarters
|
|
|
TEAR
24
DELISTED
TearLab Corporation
TEAR
| $1.2M | 1.2% |
184,824
+9,300
| +5% | +$69.1K |
2015 Q2
5 quarters
|
|
25
Abbott
ABT
$178B
| $1.19M | 1.19% |
28,175
+2,100
| +8% | +$90K |
2014 Q1
10 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q3 2016 Portfolio in Review
As of Q3 2016, Perkins Capital Management held 128 positions worth $100M, up 15% from $87.2M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Perkins Capital Management deployed $4.19M of net new capital in Q3 2016, opening 12 new positions and adding to 26 existing holdings. Its largest new stake was Tactile Systems Technology: 96,961 shares worth $1.81M.
By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 60% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was BioTelemetry, Inc., an estimated $1.98M trimmed.
- Perkins Capital Management's largest Q3 2016 buy was Tactile Systems Technology: 96,961 shares worth $1.81M.
- Perkins Capital Management added most to Assertio in Q3 2016, an estimated $964K increase.
- Perkins Capital Management's biggest Q3 2016 reduction was BioTelemetry, Inc., cutting an estimated $1.98M.
- Perkins Capital Management fully exited Boston Scientific in Q3 2016, selling an estimated $1.18M.
- Perkins Capital Management's ten largest holdings make up 34% of its $100M portfolio in Q3 2016.
- Perkins Capital Management opened 12 new positions and closed 16 in Q3 2016.
- Perkins Capital Management's portfolio value rose 15% quarter-over-quarter to $100M.
Based on Perkins Capital Management's 13F filing for Q3 2016, filed 4 Nov 2016.